文献速递前列腺增生与排尿功能障碍

维贝格龙对重度急迫性尿失禁的疗效:随机对照3期研究的事后分析

Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
PubMed 文献 · BJU Int · 2020-02-23

该事后分析基于一项随机、安慰剂对照、双盲3期研究,评估新型选择性β3肾上腺素受体激动剂维贝格龙对膀胱过度活动症(OAB)患者急迫性尿失禁(UUI)的疗效。患者按UUI严重程度分为轻度/中度(>0至<3次/天)和重度(≥3次/天)。结果显示,维贝格龙50mg和100mg在第12周均显著减少UUI发作次数并增加每次排尿量,且重度亚组同样获益,应答率超过50%。

要点

  • 维贝格龙50mg和100mg均显著减少OAB患者每日UUI发作次数,重度UUI亚组同样有效。
  • 维贝格龙显著增加每次排尿量,且在轻中度和重度UUI亚组中均显著优于安慰剂。
  • 维贝格龙组PGI应答率显著高于安慰剂,重度UUI亚组应答率也超过50%。

核心结论

  • 维贝格龙可显著减少OAB患者(包括重度UUI患者)每日UUI发作次数并增加每次排尿量,应答率超过50%,提示其是OAB伴UUI的有效治疗选择。

研究设计与样本

  • 一项随机、安慰剂对照、双盲3期研究的事后分析,纳入每日UUI发作>0次的OAB患者,按UUI严重程度分为轻度/中度(>0至<3次/天)和重度(≥3次/天)亚组。

主要发现

  • 第12周UUI发作次数变化:维贝格龙50mg、100mg和安慰剂组在所有患者中分别为-1.35、-1.47和-1.08,轻度/中度亚组为-1.04、-1.13和-0.89,重度亚组为-2.95、-3.28和-2.10。
  • 维贝格龙50mg和100mg组UUI发作次数变化在所有患者及两严重度亚组中均显著优于安慰剂。
  • 每日急迫发作次数变化:维贝格龙100mg组在所有患者和两亚组中均显著优于安慰剂;50mg组在所有患者和轻度/中度亚组中显著优于安慰剂。
  • 每次排尿量变化:维贝格龙50mg和100mg组在所有患者及两亚组中均显著大于安慰剂。
  • 日记干燥率:维贝格龙50mg和100mg组在所有患者和轻度/中度亚组中显著高于安慰剂;重度亚组中仅50mg组有显著差异。

关键数值与推荐

  • PGI应答率(评分1或2)在维贝格龙组所有患者及两亚组中均显著高于安慰剂。
  • 与UUI正常化显著相关的因素包括:维贝格龙给药、OAB病程≤37个月、基线平均每日排尿次数<12.0次、基线平均每日UUI发作次数<3.0次。

临床怎么用

  • 对于OAB伴UUI患者,维贝格龙50mg或100mg可考虑作为减少UUI发作和增加排尿量的治疗选择,重度UUI患者也可获益。

局限性

  • 本研究为3期研究的事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of a novel and selective β3-adrenoreceptor agonist vibegron on urgency urinary incontinence (UUI) in patients with overactive bladder (OAB). PATIENTS AND METHODS: A post hoc analysis was performed in patients with UUI (>0 episodes/day) who were assigned to receive vibegron or placebo in a vibegron phase 3 study. Patients were subclassified into mild/moderate (>0 to <3 UUI episodes/day) or severe UUI (≥3 UUI episodes/day) subgroup. Changes from baseline in number of UUI episodes/day, in number of urgency episodes/day, and in voided volume/micturition were compared between the groups. The percentage of patients who became UUI-free ('diary-dry' rate) and the response rate (percentage of patients with scores 1 [feeling much better] or 2 [feeling better] assessed by the Patient Global Impression scale [PGI]) were evaluated. RESULTS: Changes in numbers of UUI episodes at week 12 in the vibegron 50 mg, vibegron 100 mg and placebo groups, respectively, were -1.35, -1.47 and -1.08 in all patients, -1.04, -1.13 and -0.89 in the mild/moderate UUI subgroup, and -2.95, -3.28 and -2.10 in the severe UUI subgroup. The changes were significant in the vibegron 50 and 100 mg groups vs placebo regardless of symptom severity. Change in number of urgency episodes/day was significant in the vibegron 100 mg group vs placebo in all patients and in both severity subgroups. In the vibegron 50 mg group, a significant change vs placebo was observed in all patients and in the mild/moderate UUI subgroup. Change in voided volume/micturition was significantly greater in the vibegron 50 and 100 mg groups vs placebo in all patients, as well as in the both severity subgroups. Diary-dry rates in the vibegron 50 and 100 mg groups were significantly greater vs placebo in all patients and in the mild/moderate UUI subgroup. In the severe UUI subgroup, however, a significant difference was observed only in the vibegron 50 mg group. Response rates assessed by the PGI were significantly higher in the vibegron groups vs placebo in all patients and in the both severity subgroups. Vibegron administration, OAB duration ≤37 months, mean number of micturitions/day at baseline <12.0 and mean number of UUI episodes/day at baseline <3.0 were identified as factors significantly associated with normalization of UUI. CONCLUSIONS: Vibegron, a novel β3-adrenoreceptor agonist, significantly reduced the number of UUI episodes/day and significantly increased the voided volume/micturition in patients with OAB including those with severe UUI, with the response rate exceeding 50%. These results suggest that vibegron can be an effective therapeutic option for OAB patients with UUI.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020. PMID: 31991511. doi:10.1111/bju.15020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。